Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is a relatively common malignancy and its incidence is increasing. Prognosis in these patients is poor, and surgery, the only effective treatment, saves only a minority of patients. The number in this small group of patients might be increased by early detection of pancreatic tumours. This review examines the current status of pancreatic tumour associated proteins in the detection of pancreatic cancer. As well as existing markers, the review also reports on newer markers that may offer advantages over existing ones in the detection of pancreatic adenocarcinoma. This is particularly important because recent studies have identified high-risk groups susceptible to pancreatic cancer. Future research in pancreatic cancer should be directed at earlier detection, and tumour markers may play an important role in this process.
Audisio
R A
RA
Division of General Surgery, European Institute of Oncology, Milan, Italy.
Veronesi
P
P
Maisonneuve
P
P
Chiappa
A
A
Andreoni
B
B
Bombardieri
E
E
Geraghty
J G
JG
D000230:Adenocarcinoma / Q000175:diagnosis*; D000951:Antigens, Neoplasm / Q000097:blood; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C081241:CA 195 antigen; C074601:CA 242 antigen; D018395:CA-19-9 Antigen; C082699:CA-50 antigen; D002272:Carcinoembryonic Antigen; C059729:pancreatic associated antigen, SPan-1